Analysts' ratings for Ocular Therapeutix (NASDAQ:OCUL) over the last quarter vary from bullish to bearish, as provided by 7 analysts. The table below provides a snapshot of their recent ratings ...

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -27.59% and 37.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

BEDFORD, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience ...

Posterior and/or peripheral anterior synechia Figure 16, iris atrophy, cataract due to inflammation and/or medication and secondary glaucoma may develop.

Ocular surface disease (OSD) develops from a combination of adverse conditions that ultimately damage the surface layers of the eye. While the early symptoms of ocular surface disease might amount ...

Swan 7 also had the rare opportunity to study the ocular changes of an embryo obtained shortly after the mother contracted rubella late in the second month of pregnancy.

Ocular Therapeutix obtained FDA support to use the phase 3 SOL-R trial as the next step in the regulatory process for Axpaxli, according to a press release.

The impact of Steven-Johnson Syndrome on the eyes is particularly prominent, resulting in severe eye pain, light sensitivity, vision loss, and, in some cases, blindness.

Ocular albinism is a genetic condition that affects the eyes. It can lead to issues with vision. Learn more about ocular albinism here.

Eye infections are an important cause of vision loss worldwide and are frequently seen in outpatient and hospital settings. The authors review the epidemiology, diagnosis, and treatment of eye infe ...

Four indicated retinal vasculitis. After therapy, ocular manifestations of syphilis infection typically improved, although 1 eye presented moderate OCV and another had posterior synechia. Patients did ...